Jiangsu Hengrui Medicine Co., Ltd, a leading pharmaceutical company based in China and listed as (SHA: 600276), has received approval from the National Medical Products Administration (NMPA) for its Category 1 drug, RGL-193. This marks a significant step forward as the drug advances into clinical studies focused on Parkinson’s disease (PD).
RGL-193 is a pioneering dual AAV (Adeno-Associated Virus) therapy designed to be administered directly into the brain using stereotactic techniques. This innovative approach aims to enhance the conversion efficiency of levodopa, a standard treatment for Parkinson’s, thereby reducing the required drug dosage and minimizing dose-related adverse reactions. Furthermore, RGL-193 holds the potential to repair impaired dopaminergic neurons, which are crucial for managing the disease’s symptoms. The therapy’s ultimate goal is to delay the progression of Parkinson’s and reduce the reliance on oral anti-Parkinson’s medications.- Flcube.com
